Avionics manufacturer Garmin announced Aug. 14 that Textron Aviation has certified its runway collision avoidance software based on ADS-B In position reporting on the Cessna Caravan turboprop ...
You can read Aircraft For Sale: Today’s Top Pick at FLYINGMag.com daily. Today’s Top Pick is a 1974 Cessna 172M Skyhawk. Pilots shopping for their first aircraft after receiving their private ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
You can read Aircraft For Sale: Today’s Top Pick at FLYINGMag.com daily. Today’s Top Pick is a 1973 Cessna P337G Skymaster. Pilots who wish to step up to multiengine aircraft from high ...
Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30 ...
The longest of all happened to be undertaken by that most humble of aircraft, the Cessna 172. From December 1958 to February 1959, Bob Timm and John Cook set out to make history. The duo remained ...
Vor Bio's Trem-cel Shows Early Encouraging Data In Leukemia Patients Vor Biopharma Inc (NASDAQ: VOR) presented updated data from patients treated in the VBP101 Phase 1/2a study of trem-cel ...
If the system fails, the pilots will have to rely on older systems like VOR to navigate. But ADS-B will have even more problems. An aircraft ADS-B system needs position data to operate.
Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results